Surveillance of metabolic syndrome, hyperprolactinemia and cardiac side effects in children and adolescent treated with antipsychotic. Actuality and recommendations;Principes de surveillance des effets métaboliques, de l'hyperprolactinémie et du rythme cardiaque pour les antipsychotiques atypiques chez l'enfant et l'adolescent

Neuropsychiatrie de l'Enfance et de l'Adolescence

Volumn 58, Issue 6-7, 2010, Pages 431-438

  Bonnot, O ^a   Inaoui, R ^a   Lloret Linares, C ^b   Cohen, D ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Antipsychotic; Early Onset Schizophrenia; Hyperprolactinemia; Metabolic syndrome; Vitamin D

Indexed keywords

NEUROLEPTIC AGENT; VITAMIN D;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; HUMAN; HYPERPROLACTINEMIA; METABOLIC SYNDROME X; OSTEOPOROSIS; RISK FACTOR; SCHIZOPHRENIA; SUDDEN DEATH; TREATMENT RESPONSE; VITAMIN D DEFICIENCY;

EID: 77956455081     PISSN: 02229617     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurenf.2009.09.004     Document Type: Article

References (58)

1. Citrome L., Stroup T.S. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?. Int J Clin Pract 2006, 60(8):933-940.
2. Meyer J.M., Nasrallah H.A., McEvoy J.P., Goff D.C., Davis S.M., Chakos M., et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005, 80(1):9-18.
3. Cuzzolin L., Atzei A., Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf 2006, 5(5):703-718.
4. Hugtenburg J.G., Heerdink E.R., Tso Y.H. Psychoactive drug prescribing by Dutch child and adolescent psychiatrists. Acta Paediatr 2005, 94(10):1484-1487.
5. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192(4238):481-483.
6. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261(5562):717-719.
7. Meltzer H.Y. Clinical evidence for multiple dopamine receptors in man. Commun Psychopharmacol 1979, 3(6):457-470.
8. Woods S.W., Martin A., Spector S.G., McGlashan T.H. Effects of development on Olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 2002, 41(12):1439-1446.
9. Saland J.M. Update on the metabolic syndrome in children. Curr Opin Pediatr 2007, 19(2):183-191.
10. Cook S., Weitzman M., Auinger P., Nguyen M., Dietz W.H. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003, 157(8):821-827.
11. Weiss R., Dziura J., Burgert T.S., Tamborlane W.V., Taksali S.E., Yeckel C.W., et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004, 350(23):2362-2374.
12. Virdis A., Ghiadoni L., Masi S., Versari D., Daghini E., Giannarelli C., et al. Obesity in the childhood: a link to adult hypertension. Curr Pharm Des 2009, 15(10):1063-1071.
13. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156(11):1686-1696.
14. Malone R.P., Cater J., Sheikh R.M., Choudhury M.S., Delaney M.A. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001, 40(8):887-894.
15. Frazier J.A., Biederman J., Tohen M., Feldman P.D., Jacobs T.G., Toma V., et al. A prospective open-label treatment trial of Olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001, 11(3):239-250.
16. Ratzoni G., Gothelf D., Brand-Gothelf A., Reidman J., Kikinzon L., Gal G., et al. Weight gain associated with Olanzapine and Risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002, 41(3):337-343.
17. Grothe D.R., Calis K.A., Jacobsen L., Kumra S., DeVane C.L., Rapoport J.L., et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol 2000, 20(2):220-225.
18. Keltner N.L. Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics. Perspect Psychiatr Care 2006, 42(3):204-207.
19. Martin A., Landau J., Leebens P., Ulizio K., Cicchetti D., Scahill L., et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child. Adolesc Psychopharmacol 2000, 10(4):259-268.
20. McEvoy J.P., Lieberman J.A., Perkins D.O., Hamer R.M., Gu H., Lazarus A., et al. Efficacy and tolerability of Olanzapine, quetiapine, and Risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164(7):1050-1060.
21. Armenteros J.L., Whitaker A.H., Welikson M., Stedge D.J., Gorman J. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 1997, 36(5):694-700.
22. Findling R.L., Maxwell K., Wiznitzer M. An open clinical trial of Risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997, 33(1):155-159.
23. McDougle C.J., Stigler K.A., Erickson C.A., Posey D.J. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008, 69(Suppl 4):15-20.
24. Kelly D.L., Conley R.R., Love R.C., Horn D.S., Ushchak C.M. Weight gain in adolescents treated with Risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998, 8(3):151-159.
25. Shaw P., Sporn A., Gogtay N., Overman G.P., Greenstein D., Gochman P., et al. Childhood-onset schizophrenia: A double-blind, randomized Clozapine-Olanzapine comparison. Arch Gen Psychiatry 2006, 63(7):721-730.
26. Sikich L. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 2008, 69(Suppl 4):21-25.
27. Findling R.L. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 2008, 69(Suppl 4):9-14.
28. Gothelf D., Falk B., Singer P., Kairi M., Phillip M., Zigel L., et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with Olanzapine. Am J Psychiatry 2002, 159(6):1055-1057.
29. Patel N.C., Pharm D., Hariparsad M., Matias-Aktar M., Sorter M., Barzman D.H., et al. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol 2007, 17(3):303-311.
30. Langer G., Sachar E.J., Gruen P.H., Halpern F.S. Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency. Nature 1977, 266(5603):639-640.
31. Kuruvilla A., Srikrishna G., Peedicayil J., Kuruvilla K., Kanagasabapathy A.S. A study on serum prolactin levels in schizophrenia: correlation with positive and negative symptoms. Int Clin Psychopharmacol 1993, 8(3):177-179.
32. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C., et al. Double-blind comparison of Olanzapine versus Risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997, 17(5):407-418.
33. Breier A.F., Malhotra A.K., Su T.P., Pinals D.A., Elman I., Adler C.M., et al. Clozapine and Risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999, 156(2):294-298.
34. Chrzanowski W.K., Marcus R.N., Torbeyns A., Nyilas M., McQuade R.D. Effectiveness of long-term Aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with Olanzapine. Psychopharmacology (Berl) 2006, 189(2):259-266.
35. David S.R., Taylor C.C., Kinon B.J., Breier A. The effects of Olanzapine, Risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000, 22(9):1085-1096.
36. Montejo A.L. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 2008, 18(Suppl 2):S108-S114.
37. Szarfman A., Tonning J.M., Levine J.G., Doraiswamy P.M. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006, 26(6):748-758.
38. Lean M., De Smedt G. Schizophrenia and osteoporosis. Int Clin Psychopharmacol 2004, 19(1):31-35.
39. Sporn A.L., Vermani A., Greenstein D.K., Bobb A.J., Spencer E.P., Clasen L.S., et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007, 46(10):1349-1356.
40. Howard L., Kirkwood G., Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007, 190:129-134.
41. Kishimoto T., Watanabe K., Shimada N., Makita K., Yagi G., Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypotahmamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry 2008, 69(3):385-391.
42. Meaney A.M., O'Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 2007, 93(1-3):136-143.
43. O'Keane V., Meaney A.M. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?. J Clin Psychopharmacol 2005, 25(1):26-31.
44. Kanis J.A., Oden A., Johnell O., Jonsson B., de Laet C., Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001, 12(5):417-427.
45. Klotzbuecher C.M., Ross P.D., Landsman P.B., Abbott T.A., Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000, 15(4):721-739.
46. Halbreich U. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs 2007, 21(8):641-657.
47. Abraham G., Friedman R.H., Verghese C., de Leon J. Osteoporosis and schizophrenia: can we limit known risk factors?. Biol Psychiatry 1995, 38(2):131-132.
48. Halbreich U., Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 1996, 22(3):447-454.
49. Hummer M., Malik P., Gasser R.W., Hofer A., Kemmler G., Moncayo Naveda R.C., et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005, 162(1):162-167.
50. Bonjour J.P., Carrie A.L., Ferrari S., Clavien H., Slosman D., Theintz G., et al. Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest 1997, 99(6):1287-1294.
51. Weaver C.M. Calcium and magnesium requirements of children and adolescents and peak bone mass. Nutrition 2000, 16(7-8):514-516.
52. Holick M.F. The role of vitamin D for bone health and fracture prevention. Curr Osteoporos Rep 2006, 4(3):96-102.
53. Suhara Y. Prevention of osteoporosis by foods and dietary supplements. Vitamin D and bone metabolism. Clin Calcium 2006, 16(10):1646-1650.
54. Rizzoli R, Boonen S, Brandi ML, Nansa Burlet N, Delmas PD, Kanis J, et al. Calcium and Vitamin D in the management of osteoporosis.: The european society for clinical and economical aspects of osteoporosis and arthritis 2009. http://www.iofbonehealth.org/download/osteofound/filemanager/iof/csa/pdf/calcium-vitaminD-ESCEO.pdf.
55. Reilly J.G., Ayis S.A., Ferrier I.N., Jones S.J., Thomas S.H. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000, 355(9209):1048-1052.
56. Ray W.A., Chung C.P., Murray K.T., Hall K., Stein C.M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360(3):225-235.
57. de Castro M.J., Fraguas D., Laita P., Moreno D., Parellada M., Pascual D., et al. QTc changes after 6 months of second-generation antipsychotic treatment in children and adolescents. J Child Adolesc Psychopharmacol 2008, 18(4):381-383.
58. Nahshoni E., Spitzer S., Berant M., Shoval G., Zalsman G., Weizman A. QT interval and dispersion in very young children treated with antipsychotic drugs: a retrospective chart review. J Child Adolesc Psychopharmacol 2007, 17(2):187-194.